Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open Label, Multicenter, Single-dose, Phase 2b Clinical Study Evaluating Efficacy and Safety of Gene Therapy Using Autologous CD34+ Hematopoietic Stem Cells Transduced With the GLOBE Lentiviral Vector Using an Improved Transduction Protocol in Subjects With Transfusion-dependent Beta-thalassemia

NCT07680803 is registered in ClinicalTrials.gov with Fondazione Telethon as lead sponsor.

NCT NCT07680803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open Label, Multicenter, Single-dose, Phase 2b Clinical Study Evaluating Efficacy and Safety of Gene Therapy Using Autologous CD34+ Hematopoietic Stem Cells Transduced With the GLOBE Lentiviral Vector Using an Improved Transduction Protocol in Subjects With Transfusion-dependent Beta-thalassemia
Lead sponsor
Fondazione Telethon
Phase
Phase 2
Overall status
Recruiting
Start date
July 6, 2026
Completion date
October 31, 2030
Enrollment
9 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

transfusion-dependent beta-thalassemia